These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
802 related articles for article (PubMed ID: 18163519)
1. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519 [TBL] [Abstract][Full Text] [Related]
2. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Syversen SW; Goll GL; van der Heijde D; Landewé R; Lie BA; Odegård S; Uhlig T; Gaarder PI; Kvien TK Ann Rheum Dis; 2010 Feb; 69(2):345-51. PubMed ID: 19648126 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis. Maraina CH; Nurdayana AK; Rusni D; Azwany Y Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R; Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488 [TBL] [Abstract][Full Text] [Related]
5. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis. Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947 [TBL] [Abstract][Full Text] [Related]
6. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients. Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876 [TBL] [Abstract][Full Text] [Related]
7. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients. Zhu T; Feng L Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638 [TBL] [Abstract][Full Text] [Related]
8. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis. Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044 [TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185 [TBL] [Abstract][Full Text] [Related]
10. An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting. van Heemst J; Trouw LA; Nogueira L; van Steenbergen HW; van der Helm-van Mil AH; Allaart CF; Serre G; Holmdahl R; Huizinga TW; Toes RE; van der Woude D Arthritis Res Ther; 2015 Oct; 17():276. PubMed ID: 26437716 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis. Keskin G; Inal A; Keskin D; Pekel A; Baysal O; Dizer U; Sengül A Protein Pept Lett; 2008; 15(3):314-7. PubMed ID: 18336364 [TBL] [Abstract][Full Text] [Related]
12. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Dejaco C; Klotz W; Larcher H; Duftner C; Schirmer M; Herold M Arthritis Res Ther; 2006; 8(4):R119. PubMed ID: 16859519 [TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988 [TBL] [Abstract][Full Text] [Related]
15. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872 [TBL] [Abstract][Full Text] [Related]
16. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. El-Barbary AM; Kassem EM; El-Sergany MA; Essa SA; Eltomey MA J Rheumatol; 2011 May; 38(5):828-34. PubMed ID: 21362765 [TBL] [Abstract][Full Text] [Related]
17. Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis. Koivula MK; Heliövaara M; Rissanen H; Palosuo T; Knekt P; Immonen H; Risteli J Ann Rheum Dis; 2012 Oct; 71(10):1666-70. PubMed ID: 22419777 [TBL] [Abstract][Full Text] [Related]
18. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Wagner E; Skoumal M; Bayer PM; Klaushofer K Rheumatol Int; 2009 Sep; 29(11):1315-21. PubMed ID: 19184032 [TBL] [Abstract][Full Text] [Related]
19. [Significance and diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody and anti-mutated citrullinated vimentin antibodies in patients with serum negative rheumatoid arthritis]. Qu SJ; Ye H; Jia RL; Li ZG Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):933-936. PubMed ID: 27987492 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of the anti-Sa antibody compared with the anti-cyclic citrullinated peptide antibody in rheumatoid arthritis. Iwaszkiewicz C; Puszczewicz M; Białkowska-Puszczewicz G Int J Rheum Dis; 2015 Jan; 18(1):46-51. PubMed ID: 25488711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]